Kazakhstan

Population 2018 18 million

<table>
<thead>
<tr>
<th>Estimates of TB burden*, 2018</th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>12 (8.1–18)</td>
<td>68 (44–97)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.73 (0.47–1)</td>
<td>4 (2.6–5.7)</td>
</tr>
<tr>
<td>MDR/RR-TB incidence**</td>
<td>4.8 (3–6.9)</td>
<td>26 (16–38)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>0.43 (0.36–0.51)</td>
<td>2.3 (1.9–2.8)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.048 (0.014–0.1)</td>
<td>0.26 (0.08–0.56)</td>
</tr>
</tbody>
</table>

Estimated proportion of TB cases with MDR/RR-TB, 2018

- New cases 27% (26–28)
- Previously treated cases 64% (63–66)

TB case notifications, 2018

- Total new and relapse 12 832
  - % tested with rapid diagnostics at time of diagnosis 89%
  - % with known HIV status 95%
  - % pulmonary 91%
  - % bacteriologically confirmed** 88%
  - % children aged 0-14 years 2%
  - % women 38%
  - % men 60%
- Total cases notified 13 361

Universal health coverage and social protection

- TB treatment coverage (notified/estimated incidence), 2018 100% (72–160)
- TB patients facing catastrophic total costs
- TB case fatality ratio (estimated mortality/estimated incidence), 2018 4% (3–6)
- TB/HIV care in new and relapse TB patients, 2018
  - Number (%)
    - on antiretroviral therapy 717 6%
  - Patients with known HIV status who are HIV-positive 689 96%

Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance**
  - New cases 94%
  - Previously treated cases 90%

Laboratory-confirmed cases*

- MDR/RR-TB: 4 869, XDR-TB: 336
- MDR/RR-TB: 4 814, XDR-TB: 386
- MDR/RR-TB cases tested for resistance to second-line drugs 4 384

Treatment success rate and cohort size

- New and relapse cases registered in 2017 91% 8 589
- Previously treated cases, excluding relapse, registered in 2017 82% 250
- MDR/RR-TB cases started on second-line treatment in 2016 80% 6 260
- XDR-TB cases started on second-line treatment in 2016 48% 435

TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment 53%
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment 20% (19–22)

TB financing, 2019

- National TB budget (US$ millions) 134
- Funding source: 94% domestic, 6% international, 0% unfunded

* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Calculated for pulmonary cases only
* Includes cases with unknown previous TB treatment history
** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
Generated: 2020-01-14 Data: www.who.int/tb/data